EU/3/10/769: Orphan designation for the treatment of post-polycythaemia vera myelofibrosis

27000

Overview

On 25 August 2010, orphan designation (EU/3/10/769) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treatment of post-polycythaemia vera myelofibrosis.

The sponsorship was transferred to Baxter Innovations GmbH, Austria, in March 2015.

The sponsorship was transferred to CTI Life Sciences Ltd, United Kingdom, in November 2016 and subsequently to CTI Life Sciences Deutschland GmbH, Germany, in May 2019.

This medicine is now known as pacritinib.

Key facts

Active substance
27000
Intended use
Treatment of post-polycythaemia vera myelofibrosis
Orphan designation status
Positive
EU designation number
EU/3/10/769
Date of designation
25/08/2010
Sponsor


Universitaetsstrasse 71 
Lindenthal 
Cologne 
North Rhine-Westphalia 
50931 
Germany
Tel. +49 51187989019
E-mail: contactus@CTI-lifesciences.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating